Will David Sinclair be regularly taking a SGLT2 inhibitor (canagliflozin, empagliflozin) by the end of 2025?
Basic
2
Ṁ202026
50%
chance
1D
1W
1M
ALL
This question is managed and resolved by Manifold.
Get
1,000
and3.00
Related questions
Related questions
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?
78% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
7% chance
Will Kim Jong Un start taking Ozempic (or any GLP-1) by the end of 2025?
36% chance
Will Mike Lustgarten start to regularly ANY of {rapamycin, metformin, acarbose, SGLT2 inhibitors) by the end of 2027?
58% chance
Will Morgan Levine start to regularly ANY of {rapamycin, metformin, acarbose, SGLT2 inhibitors) by the end of 2027?
54% chance
Will Bryan Johnson still be regularly taking metformin by EOY 2024?
57% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024
36% chance
Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
7% chance